The story archive

Every discovery.
A little clearer.

Browse the collection, follow a topic, or find the story that sparked your curiosity.

Topic

500 published stories

Oncology

How a protein shield helps ovarian cancer resist chemotherapy

Ovarian cancer can be notoriously difficult to treat, especially when the tumor stops responding to common chemotherapy drugs like cisplatin. Researchers have now identified a key protein, called RUNX2, that helps these cancer cells survive. When this protein is active, it protects the cancer cells from a natural type of cell death called ferroptosis. Ferroptosis is a process that normally destroys damaged or dangerous cells using iron. By suppressing this iron-driven cell death, RUNX2 allows the cancer cells to become highly resistant to chemotherapy. The researchers discovered that RUNX2 does not act alone. It receives a specific chemical upgrade, a process known as palmitoylation, driven by another protein named ZDHHC14. This modification is essential for switching RUNX2 into its fully protective mode. Once activated, RUNX2 turns on a specific downstream genetic pathway, known as the YAP1/GLS1 axis, which ultimately shields the tumor from drugs. Interestingly, when scientists introduced a specific mutation called RUNX2-C13S into the cells, they were able to successfully block this chemical upgrade entirely.

PubMed · 1 min read

Oncology

Tiny Particles Could Help Treat Brain Cancer, but Hurdles Remain

Glioblastoma is an aggressive type of brain cancer that is notoriously difficult to treat. One of the biggest hurdles for doctors is the blood-brain barrier. This highly selective filter protects our brains from toxins, but it also stops helpful medications from reaching tumors. On top of this, brain tumors frequently develop a stubborn resistance to drugs. To solve these problems, researchers are looking at nanoparticles. These microscopic delivery vehicles offer a versatile way to sneak past the brain's natural defenses and reverse a tumor's ability to resist treatment. By tweaking the design of these nanoparticles, scientists can do much more than just drop off medication. These tiny platforms are customized to release drugs at a carefully controlled rate and target tumor cells with high precision. They can also be equipped to attack the cancer in creative ways. For example, modified nanoparticles can use light and heat to destroy cancer cells, trigger a specific type of cellular self-destruction known as ferroptosis, and alter the biological environment surrounding the tumor to make it weaker. Despite this incredible promise, the technology is still facing some serious growing pains. Moving these treatments from the laboratory into real-world clinics is currently held back by several major challenges. Tumors are highly uneven and complex, which makes targeting them a moving goalpost. Additionally, figuring out how to manufacture these advanced particles safely and on a massive scale remains a difficult puzzle for scientists to solve.

PubMed · 2 min read

Oncology

Seven Metabolic Genes Could Help Predict Brain Cancer Survival

Glioblastoma is a notoriously deadly form of brain cancer, and doctors have long struggled with limited tools to predict how individual patients will fare. Now, researchers have uncovered a new way to forecast patient outcomes by looking at a tumor's metabolism. By focusing on a specific chemical pathway called propionate metabolism, scientists identified a unique signature of seven genes. This genetic fingerprint allowed the team to accurately divide patients into high-risk and low-risk groups with drastically different survival times. The researchers also mapped out exactly what makes the high-risk tumors so aggressive. These high-risk cancers are heavily associated with an environment that actively shuts down the body's natural defenses. They show high levels of immune checkpoints, which are cellular signals that trick the immune system into leaving the tumor alone. By examining the tumors cell by cell, the team confirmed that these seven metabolic genes are highly active specifically inside the malignant cancer cells, rather than in the surrounding supportive tissue. Additionally, the study revealed that these risk groups carry distinct genetic hallmarks. Patients in the high-risk category frequently have mutations in a key gene known as RB1, while those in the low-risk group are more likely to have mutations in a gene called IDH1. Together, these clues paint a much clearer picture of the biology driving the most dangerous brain tumors.

PubMed · 2 min read

Drug Development

Old Drugs, New Tricks: Repurposing Medicines for Pandemics

When a new virus emerges, developing a treatment from scratch takes years. To speed things up, scientists often look at existing medications to see if they can fight new threats, a process known as drug repurposing. A recent sweeping review, called a horizon scan, searched medical literature and clinical trial databases to see how many existing drugs are being tested against viruses with pandemic potential. The researchers found 196 repurposed drug candidates in the scientific literature, with 58 currently in active clinical development. These investigated medicines mostly fall into categories like direct-acting antivirals, which stop viruses from multiplying, alongside medications that calm the immune system and reduce inflammation. However, the study revealed that active human testing is highly concentrated. Almost all interventional clinical trials are restricted to just two viruses: SARS-CoV-2 and influenza. Specifically, 29 treatments for SARS-CoV-2 and two for influenza have made it to advanced Phase III trials, which is the final testing step before general approval. For other highly dangerous viruses like Ebola, Marburg, MERS, and mpox, the research is lagging. Potential treatments for these diseases are still stuck in early exploratory or laboratory testing phases. The study authors also strongly caution that just because a drug is being investigated does not mean it will actually work. Before any repurposed medicine can be given to patients, it still requires rigorous lab validation and testing to prove it is safe, effective, and behaves correctly in the human body.

PubMed · 2 min read

Immunology

The Surprising Drivers of Childhood Vaccination Rates in Somalia

Childhood vaccines are one of the most reliable ways to keep kids healthy, but reaching every child remains a major challenge in many parts of the world. In a recent sweeping review of healthcare data in Somalia, researchers sought to understand exactly how many children are getting their shots and what factors influence those medical decisions. By pooling data from 11 different studies conducted between 2010 and 2025, the team found that overall vaccination rates remain alarmingly low. Only 42.2 percent of children are fully immunized, and a mere 16.1 percent have completed the full series of four basic vaccines. When the researchers looked into what makes a child more likely to be vaccinated, they found a mix of expected patterns and striking surprises. Unsurprisingly, mothers who had formal education and those who gave birth in medical facilities were significantly more likely to have their infants immunized. However, conventional wisdom was turned upside down when looking at geography. Children living in rural areas were actually 1.55 times more likely to get their shots than kids living in urban centers. The most unexpected discovery involved prenatal visits. Logically, mothers who see doctors frequently before giving birth should be more connected to the medical system. Yet, mothers who attended four or more pregnancy checkups were actually much less likely to ensure their children were immunized. The authors caution that because these findings rely on observational snapshot studies, they can highlight these unusual patterns but cannot definitively prove what is causing them.

PubMed · 2 min read

Oncology

How the PSD3 Protein Helps Esophageal Tumors Hide from the Immune System

Esophageal squamous cell carcinoma, or ESCC, is a difficult disease to treat because it is notoriously good at hiding from the body's immune system. Scientists have known that a cellular recycling process called autophagy plays a role in this disappearing act. Now, researchers have identified a specific protein called PSD3 that appears to be a major accomplice. When looking at ESCC tissues, the team found that PSD3 is highly active, and patients with elevated levels of this protein tend to face worse clinical outcomes. To understand how this protein works, researchers performed experiments to block or knock down PSD3 in both human and mouse cell models. Without PSD3, the cancer cells could not carry out their normal recycling process efficiently. Even more importantly, blocking PSD3 caused an increase in MHC-I proteins. These proteins act like tiny red flags on the surface of a cell, signaling to the immune system that a threat is present. In mouse models, this increase in MHC-I proteins successfully drew more cancer-fighting immune cells into the tumors. The researchers also discovered that PSD3 works in a complex chain of events. When they silenced another recycling gene called ATG7 after blocking PSD3, it selectively restored a specific immune molecule called HLA-E, though other similar molecules remained unchanged. While these findings are exciting, the researchers note that this work is still in its early stages. Because the experiments were conducted in laboratory cell cultures and animal models, scientists need to do much more research to map out the exact chemical pathways and immune functions before this knowledge can be translated to human patients.

PubMed · 2 min read

Oncology

Mapping New Treatments for a Rare Soft Tissue Tumor

Solitary fibrous tumors are an exceedingly rare type of cancer classified as a soft tissue sarcoma. For a long time, doctors considered these tumors to be indolent, meaning they tend to grow slowly and pose little immediate threat. However, medical data now shows that up to 50 percent of cases will eventually return or spread to other parts of the body, even years after surgeons have completely removed the initial growth. When the cancer reaches this advanced or metastatic stage, it becomes a significant clinical challenge that requires effective, full-body treatments. Historically, oncologists relied on standard chemotherapy drugs called anthracyclines to fight the spreading disease, but these traditional treatments have demonstrated very limited success. Instead, a recent review of medical strategies highlights a major shift toward antiangiogenic therapies. These are specialized drugs designed to cut off the new blood vessels that tumors build, starving the cancer of the nutrients it needs to grow. Today, doctors increasingly favor these blood-starving agents as the standard first line of defense for advanced tumors. When chemotherapy is still required, specialists are turning to alternative drug combinations, such as pairing an alkylating agent like dacarbazine with a microtubule inhibitor like trabectedin, which both work to stop cancer cells from dividing. The review emphasizes that while scientists are also exploring cutting-edge immune system treatments and targeted molecular therapies, these modern approaches remain in the early stages of clinical evaluation and require further validation before becoming standard practice.

PubMed · 2 min read

Drug Development

Meet the AI Scientists Accelerating Medical Research

Tech organizations like Google DeepMind and Edison are building "AI scientists" to act as digital research partners. Recently detailed in the journal Nature, these new artificial intelligence tools aim to automate the traditional scientific process. Instead of just answering simple questions, these programs can generate original hypotheses, design lab experiments, and interpret complex data to help human researchers solve biological mysteries. The early results are highly promising. DeepMind's tool, called Co-Scientist, has successfully identified new potential targets for treating liver scarring and predicted ways to repurpose existing drugs for a severe blood cancer known as acute myeloid leukemia. Similarly, Edison's AI, named Robin, proposed novel ways to treat a common blinding eye condition called dry age-related macular degeneration. Impressively, Robin's unique treatment ideas were later tested and validated in lab experiments using real human eye cells. Building on this momentum, Edison has introduced an upgraded platform called Kosmos. This system is already partnering with the pharmaceutical company Incyte to sort through massive amounts of medical evidence and build predictive models for new therapies currently in the company's development pipeline.

GEN · 1 min read

Oncology

Circular RNA: The tiny genetic loops offering new clues to cancer

Inside our cells, genetic instructions are typically carried by linear strands of a molecule called messenger RNA, or mRNA. But scientists are paying closer attention to a different shape entirely: circular RNAs. Unlike their straight-line cousins, these molecules form a continuous, unbroken loop. Because they have no exposed ends, they are highly stable. They are also highly specific, meaning different types of tissues and cells produce their own unique sets of these loops. Even though they are abundant in the body, they are usually found in lower amounts than traditional linear RNA. Researchers have discovered that these genetic loops behave very differently when cancer is present. In tumor cells, the normal patterns of circular RNA are frequently disrupted. Mounting evidence shows that these molecules actually play major roles in how tumors start, how they grow, and how they interact with the body's immune system. Interestingly, some of the circular RNAs tied to cancer do not just stay inside the tumor. They can travel through the bloodstream and survive for long periods in blood serum. Because they are so stable and specific to certain cells, scientists believe these floating loops could eventually be used as biomarkers, which are measurable biological signs used to detect disease. By testing a patient's blood, doctors might one day be able to diagnose cancer or predict how a tumor will behave.

PubMed · 2 min read

Oncology

How Survivorship Programs Help Colorectal Cancer Patients Thrive

Beating colorectal cancer is a major milestone, but the journey rarely ends when treatment stops. Many patients face lingering physical and emotional hurdles. To help them navigate this transition, medical teams often offer survivorship programs, which are structured care plans designed to support long-term recovery. A recent comprehensive review of medical literature reveals that these programs genuinely work, significantly boosting both the physical and mental well-being of people recovering from the disease. Researchers reached this conclusion by analyzing data from 22 randomized controlled trials, the gold standard for medical research where patients are randomly assigned to receive an intervention or standard care. These trials tracked 2,949 colorectal cancer survivors. By combining the results from 13 of these studies into one large statistical evaluation, known as a meta-analysis, the team found clear, measurable improvements in the patients' health-related quality of life across both physical and emotional domains. While the findings are promising, the researchers noted a few important caveats. The overall quality of the evidence was rated as low to moderate. Furthermore, the studies varied widely in their methods and specific results, an issue scientists call statistical heterogeneity. Even with these differences, the overarching trend strongly supports the use of structured care after cancer treatment.

PubMed · 2 min read

Oncology

How a Virus Changes the Genetics and Survival of a Rare Liver Cancer

Combined hepatocellular-cholangiocarcinoma is a rare and complex type of liver cancer. Because it is so uncommon, doctors have often struggled to predict how it will behave in different people. A recent study investigated whether a viral infection, such as viral hepatitis, changes the course of this disease. The researchers uncovered a striking trend. Patients whose cancer was linked to a viral infection lived significantly longer, surviving a median of 49.5 months compared to just 20.0 months for those without a viral connection. To understand why non-viral tumors might be more deadly, the scientific team analyzed the genetic makeup of the cancers. They found that tumors without a viral origin were packed with a distinct set of genetic mutations, including alterations in genes known as IDH and TGFBR1. These specific mutations act like a biological accelerator for the cancer. They are closely linked to changes that allow tumors to rewire their internal metabolism, multiply rapidly, escape the natural defense pathways of the body, and spread to other organs. However, the researchers caution that these discoveries are still in the early stages. Because the study pooled survival data from past clinical case reports with varying follow-up times, the team could not run traditional time-based survival analyses. They describe their work as a starting point designed to generate new ideas. To confirm these genetic patterns, future researchers will need to track new groups of patients prospectively using standardized genetic testing.

PubMed · 2 min read

Oncology

How Cancers Hijack a Vital Protein to Evade Cell Death

Deep inside our brains, a microscopic pump called the cystine/glutamate antiporter is hard at work keeping our cells healthy. This biological machinery has two critical jobs. First, it imports materials needed to create glutathione, which acts as a powerful antioxidant to protect cells from damage. Second, it regulates glutamate, a crucial chemical messenger that helps brain cells communicate. Without this intricate balancing act, our nervous system simply could not function properly. However, cancer cells have figured out a way to exploit this life-saving machinery. Researchers have discovered that many different types of cancer produce abnormally high levels of a specific part of this pump, known as the xCT subunit. By cranking up the production of xCT, tumors effectively shield themselves from ferroptosis, a specialized type of programmed cell death. In short, cancer cells hijack a system meant to protect healthy cells and use it to guarantee their own survival. To figure out exactly how cancers manipulate this system, scientists recently conducted a comprehensive review of existing research. They mapped out the complex instructions that govern xCT production, discovering that cells can control this subunit at virtually every biological stage. From the initial reading of genetic code to the final construction and interaction of the protein, the researchers identified numerous distinct pathways that cancers might use to build their cellular shield.

PubMed · 2 min read